Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
Alpine Immune Sciences(ALPN) Zacks Investment Research·2024-04-13 01:41
Alpine Immune Sciences (ALPN) signed a definitive agreement with Vertex Pharmaceuticals (VRTX) . Per the terms, the pharma giant will acquire all outstanding shares of Alpine for $65 per share in cash, aggregating to $4.9 billion.A clinical-stage pharmaceutical company, Alpine is engaged in the development of multi-functional therapies targeting both autoimmune and inflammatory diseases.The acquisition will also include Alpine’s lead asset, povetacicept (formerly ALPN-303), designed to target two proteins, ...